{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:30:04Z","timestamp":1792193404900,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ajog.2021.03.024","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T23:48:29Z","timestamp":1625010509000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently needed"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-1336","authenticated-orcid":false,"given":"Edith","family":"Roset Bahmanyar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk J.","family":"Out","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl3","key":"10.1016\/j.ajog.2021.03.024_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-0528.2006.01120.x","article-title":"The preterm parturition syndrome","volume":"113","author":"Romero","year":"2006","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.03.024_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajog.2010.08.009","article-title":"The \u201cGreat Obstetrical Syndromes\u201d are associated with disorders of deep placentation","volume":"204","author":"Brosens","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2021.03.024_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","article-title":"Global and regional estimates of preeclampsia and eclampsia: a systematic review","volume":"170","author":"Abalos","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2021.03.024_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.semperi.2017.04.009","article-title":"Global disparities in maternal morbidity and mortality","volume":"41","author":"Small","year":"2017","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.03.024_bib7","doi-asserted-by":"crossref","first-page":"123.e1","DOI":"10.1016\/j.ajog.2020.01.026","article-title":"Reduction in racial disparities in severe maternal morbidity from hemorrhage in a large-scale quality improvement collaborative","volume":"223","author":"Main","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.semperi.2017.08.010","article-title":"Racial and ethnic differences in preterm birth: a complex, multifactorial problem","volume":"41","author":"Manuck","year":"2017","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2021.03.024_bib9","doi-asserted-by":"crossref","first-page":"S455","DOI":"10.1016\/j.ajog.2018.11.713","article-title":"690: racial disparities in preterm birth risk by risk factor grouping","volume":"220","author":"Chambers","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib10","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1080\/14767058.2019.1581522","article-title":"Preeclampsia outcomes at delivery and race","volume":"33","author":"Gyamfi-Bannerman","year":"2020","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib13","doi-asserted-by":"crossref","first-page":"100477","DOI":"10.1016\/j.ssmph.2019.100477","article-title":"Income inequality and racial disparities in pregnancy-related mortality in the US","volume":"9","author":"Vilda","year":"2019","journal-title":"SSM Popul Health"},{"key":"10.1016\/j.ajog.2021.03.024_bib14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cvr\/cvu012","article-title":"Incidence and prevalence of pregnancy-related heart disease","volume":"101","author":"Sliwa","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ajog.2021.03.024_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ajog.2004.06.043","article-title":"Defining standards of care in maternal-fetal medicine","volume":"191","author":"Norwitz","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib17","doi-asserted-by":"crossref","first-page":"474.e1","DOI":"10.1016\/j.ajog.2013.02.016","article-title":"Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study","volume":"208","author":"Hermes","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib18","doi-asserted-by":"crossref","first-page":"374.e1","DOI":"10.1016\/j.ajog.2011.07.015","article-title":"A\u00a0systematic review of severe morbidity in infants born late preterm","volume":"205","author":"Teune","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib19","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.jacc.2018.12.092","article-title":"Long-term cardiovascular risks associated with adverse pregnancy outcomes: JACC Review Topic of the Week","volume":"73","author":"Lane-Cordova","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ajog.2021.03.024_bib20","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3390\/ijms18122628","article-title":"Adverse intrauterine environment and cardiac miRNA expression","volume":"18","author":"Lock","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajog.2021.03.024_bib21","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1471-0528.15240","article-title":"Epigenetics and reproductive medicine: Scientific Impact Paper no. 57","volume":"125","author":"Huntriss","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.03.024_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/biof.1542","article-title":"The role of epigenetic changes in preeclampsia","volume":"45","author":"Kamrani","year":"2019","journal-title":"BioFactors"},{"key":"10.1016\/j.ajog.2021.03.024_bib23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ajog.2015.05.047","article-title":"Should pregnant women be included in phase IV clinical drug trials?","volume":"213","author":"Briggs","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib24","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ajog.2005.02.100","article-title":"Use of over-the-counter medications during pregnancy","volume":"193","author":"Werler","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM200104123441504","article-title":"The teratogenicity of anticonvulsant drugs","volume":"344","author":"Holmes","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajmg.c.30313","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","author":"Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.ajog.2021.03.024_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajog.2014.04.040","article-title":"Drug labeling in the practice of obstetric anesthesia","volume":"212","author":"Carvalho","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib29","article-title":"Randomized trials of retosiban versus placebo or atosiban in spontaneous preterm labor","author":"Saade","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2021.03.024_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajog.2019.05.044","article-title":"Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes","volume":"221","author":"Brosens","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14767050902866804","article-title":"The great obstetrical syndromes","volume":"22","author":"Di Renzo","year":"2009","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/uog.18816","article-title":"ASPRE trial: performance of screening for preterm pre-eclampsia","volume":"50","author":"Rolnik","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.placenta.2011.03.010","article-title":"Animal models of preeclampsia; uses and limitations","volume":"32","author":"McCarthy","year":"2011","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.03.024_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.tem.2004.10.009","article-title":"Animal models of preterm birth","volume":"15","author":"Elovitz","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ajog.2021.03.024_bib35","first-page":"84","article-title":"Placental structure, function and drug transfer","volume":"15","author":"Griffiths","year":"2015","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"key":"10.1016\/j.ajog.2021.03.024_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2016.08.002","article-title":"Placental control of drug delivery","volume":"116","author":"Al-Enazy","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajog.2021.03.024_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.07.050","article-title":"What is the placenta?","volume":"213","author":"Burton","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/clpt.2011.66","article-title":"The human placental perfusion model: a systematic review and development of a model to predict in\u00a0vivo transfer of therapeutic drugs","volume":"90","author":"Hutson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"SupplA","key":"10.1016\/j.ajog.2021.03.024_bib39","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.placenta.2006.11.002","article-title":"Animal models of human placentation--a review","volume":"28","author":"Carter","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2021.03.024_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/psp4.12274","article-title":"Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations","volume":"7","author":"Ke","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ajog.2021.03.024_bib41","unstructured":"ICH expert working group, detection of reproductive and developmental toxicity for human pharmaceuticals s5(r3), final version adopted on 18 february 2020, https:\/\/database.ich.org\/sites\/default\/files\/S5-R3_Step4_Guideline_2020_0218_1.pdf, Accessed March 4, 2021."},{"key":"10.1016\/j.ajog.2021.03.024_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2021.01.022","article-title":"The\u00a0coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations","author":"Stafford","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib45","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0890-6238(93)90025-3","article-title":"Assessment of the effectiveness of animal developmental toxicity testing for human safety","volume":"7","author":"Newman","year":"1993","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajog.2021.03.024_bib49","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/AAC.02613-13","article-title":"Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery","volume":"58","author":"Elkomy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2021.03.024_bib50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2174\/138920006778017777","article-title":"Thalidomide metabolism and hydrolysis: mechanisms and implications","volume":"7","author":"Lepper","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ajog.2021.03.024_bib51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1681\/ASN.V391575","article-title":"Angiotensin-converting enzyme inhibitor fetopathy","volume":"3","author":"Pryde","year":"1993","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ajog.2021.03.024_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0192623312464311","article-title":"On-target and off-target-based toxicologic effects","volume":"41","author":"Rudmann","year":"2013","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ajog.2021.03.024_bib53","doi-asserted-by":"crossref","first-page":"17603","DOI":"10.1038\/s41598-019-54180-4","article-title":"A\u00a0framework for identification of on- and off-target transcriptional responses to drug treatment","volume":"9","author":"Huang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2021.03.024_bib54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ajog.2005.06.020","article-title":"A\u00a0comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women","volume":"193","author":"McCullough","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib56","doi-asserted-by":"crossref","first-page":"724591","DOI":"10.1155\/2012\/724591","article-title":"Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers","volume":"2012","author":"Gedeon","year":"2012","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.ajog.2021.03.024_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1067\/mob.2002.125740","article-title":"Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks?","volume":"187","author":"Doering","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/AOG.0000000000003787","article-title":"Accelerated approval of 17\u03b1-hydroxyprogesterone caproate: a cautionary tale","volume":"135","author":"Godlewski","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajog.2020.09.045","article-title":"A\u00a0chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth","volume":"224","author":"Nelson","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib60","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMra1209764","article-title":"Two hundred years of progress in the practice of midwifery","volume":"367","author":"Greene","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.03.024_bib61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ajog.2020.06.031","article-title":"Advancing human health in the decade ahead: pregnancy as a key window for discovery: a\u00a0Burroughs Wellcome Fund Pregnancy Think\u00a0Tank","volume":"223","author":"Sadovsky","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ajog.2020.07.021","article-title":"Maternal mortality in the United States: research gaps, opportunities, and priorities","volume":"223","author":"Chinn","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.03.024_bib67","unstructured":"House Republican Policy Committee. Guide to the issues: vaccine approval and operation warp Speed. Available at: https:\/\/republicanpolicy.house.gov\/sites\/republicanpolicy.house.gov\/files\/documents\/Vaccine%20Approval%20and%20Operation%20Warp%20Speed%20FINAL.pdf. Accessed March 09, 2012."}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821001885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821001885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:36:11Z","timestamp":1762079771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821001885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0002937821001885"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.03.024","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Women and babies are dying from inertia: a collaborative framework for obstetrical drug development is urgently needed","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.02.032","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}